Edwards Lifesciences Corporation Stock News

Investors are optimistic about Edwards Lifescience's (EW) substantial growth across each of its four product groups.

Edwards Lifesciences (EW) outperforms the industry, owing to a robust 2023 fourth-quarter performance, as well as the strong potential in the TMTT division.

We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.

Historically viewed as a defensive area, health care also boasts many growth aspects and benefits from advances in technology.

Edwards Lifesciences' (EW) recent study provides insights into the actual performance of small Edwards valves and reaffirms the excellent outcomes for patients receiving SAPIEN TAVR.

With the Critical Care spin-off, Edwards (EW) is looking to pursue growth in TAVR, TMTT and Surgical, as well as new investments in interventional heart failure technologies.

Investors interested in Medical - Instruments stocks are likely familiar with Hologic (HOLX) and Edwards Lifesciences (EW). But which of these two stocks offers value investors a better bang for their

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Investors are optimistic about Edward Lifesciences' (EW) progress with the Structural Heart business and strong TAVR potential.

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024. Bernard Zovighian, chi

Edwards (EW) is demonstrating the strong performance of the SAPIEN 3 Ultra valve in the United States, Europe and Rest of World.

Here are three stocks, GMED, GKOS and PRCT, which are expected to beat earnings estimates in the ongoing reporting cycle.

Edwards Lifesciences' (EW) Q4 revenues register year-over-year growth on its strong differentiated portfolio of advanced therapies.

Edwards Lifesciences Corporation (EW) Q4 2023 Earnings Call Transcript

Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare wit